The 340B Program: Why It Avoids Budget Scrutiny

Why It Matters

The 340B program reduces federal tax revenue while expanding nonprofit hospital subsidies, highlighting a hidden fiscal cost that demands transparent oversight and possible policy reform.

Key Takeaways

• 340B discounts shift revenue from pharma to nonprofit hospitals.
• Program grew from 90 to over 2,600 participants.
• Hospitals bill insurers at full rates, keeping discount difference tax‑free.
• 340B functions like a hidden tax expenditure, evading budget oversight.
• Transparency needed for federal subsidies to the health‑care safety net.

Summary

The video examines the 340B drug pricing program, a federal initiative that requires pharmaceutical manufacturers to sell medicines to eligible hospitals at deep discounts. Originally limited to roughly 90 providers, the program now includes more than 2,600 hospitals, many of which are nonprofit safety‑net institutions.

By purchasing drugs at discounted rates yet billing insurers at standard prices, participating hospitals capture the price differential as untaxed revenue. This mechanism diverts profit from for‑profit drug makers to nonprofit hospitals, effectively reducing taxable income and lowering federal tax receipts. Although the program is not part of the tax code, its fiscal impact mirrors that of a tax expenditure.

The presenter likens 340B to a “government‑directed transfer” that operates outside traditional budgetary scrutiny, calling it a “hidden tax expenditure.” He references a Health Affairs Forefront article co‑authored with Ike Brannon that details the program’s opaque financial effects.

Because the subsidy bypasses standard budget oversight, policymakers risk underestimating its cost to the Treasury. Greater transparency and potential reform could ensure that subsidies to the health‑care safety net are both effective and fiscally accountable.

Original Description

Although 340B does not operate through the tax code, its economic effects mirror those of a tax expenditure. Recognizing it as such would not prejudge the program’s merits but would force a long-overdue accounting of its costs and encourage a more rational discussion of reform.

In this video, Anthony Lo Sasso from the University of Madison-Wisconsin explains his recent Health Affairs Forefront article.

Read the article: https://www.healthaffairs.org/content/forefront/340b-drug-pricing-program-hidden-tax-expenditure

---

Visit Health Affairs: http://www.healthaffairs.org

Subscribe and Listen to our Podcasts: https://www.healthaffairs.org/podcasts

Sign up for our free Newsletters: https://www.healthaffairs.org/newsletters